Mergers & Acquisitions Mergers & Acquisitions

SK Capital Partners files buyout of drugmaker Seqens for EU review

By Natalie McNelis
  • 09 Nov 2021 05:15
  • 09 Nov 2021 05:53
SK Capital Partners has asked the EU merger regulator for permission to acquire a majority stake in Seqens, a developer and maker of pharmaceutical ingredients, according to an update on the European Commission's register of deals today. 

The regulator has set a Dec. 13 deadline to decide on the deal.

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News